Maternal medicine

You have free access to this content

Association between antidepressant drug use during pregnancy and child healthcare utilisation

  1. TF Ververs1,2,
  2. K van Wensen3,
  3. MW Freund4,
  4. M van der Heide5,
  5. GHA Visser5,
  6. AFAM Schobben1,2,
  7. LTW de Jong-van den Berg6,
  8. ACG Egberts1,2

Article first published online: 14 AUG 2009

DOI: 10.1111/j.1471-0528.2009.02292.x

Issue

BJOG: An International Journal of Obstetrics & Gynaecology

BJOG: An International Journal of Obstetrics & Gynaecology

Volume 116, Issue 12, pages 1568–1577, November 2009

Additional Information

How to Cite

Ververs, T., van Wensen, K., Freund, M., van der Heide, M., Visser, G., Schobben, A., de Jong-van den Berg, L. and Egberts, A. (2009), Association between antidepressant drug use during pregnancy and child healthcare utilisation. BJOG: An International Journal of Obstetrics & Gynaecology, 116: 1568–1577. doi: 10.1111/j.1471-0528.2009.02292.x

Author Information

  1. 1

    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

  2. 2

    Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands

  3. 3

    VGZ Health Insurance Company, Nijmegen, The Netherlands

  4. 4

    Department of Pediatric Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands

  5. 5

    Department of Perinatology and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands

  6. 6

    Department of Pharmacy, Unit Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Utrecht, The Netherlands

*ACG Egberts, Department of Clinical Pharmacy, University Medical Center Utrecht, D00.218, PO Box 85500, 3508 GA Utrecht, The Netherlands. Email a.c.g.egberts@umcutrecht.nl

Publication History

  1. Issue published online: 9 OCT 2009
  2. Article first published online: 14 AUG 2009
  3. Accepted 9 June 2009. Published Online 14 August 2009.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (222K)

References

  • 1
    Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62:863–70.
  • 2
    Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007;114:1055–64.
    Direct Link:
  • 3
    Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008;65: 600–6.
    Direct Link:
  • 4
    Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008;198:194 e1–5.
  • 5
    Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC. Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord 2007;98:109–15.
  • 6
    Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823–7.
    Direct Link:
  • 7
    Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18–27.
    Direct Link:
  • 8
    Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007;29:918–26.
  • 9
    Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675–83.
  • 10
    Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579–87.
  • 11
    Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701–4.
  • 12
    Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1075–85.
    Direct Link:
  • 13
    Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17:801–6.
    Direct Link:
  • 14
    Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301–8.
    Direct Link:
  • 15
    Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695–705.
  • 16
    Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684–92.
  • 17
    Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293:2372–83.
  • 18
    Buitelaar JK, Huizink AC, Mulder EJ, de Medina PG, Visser GH. Prenatal stress and cognitive development and temperament in infants. Neurobiol Aging 2003;24 Suppl. 1:S53–60; Discussion S7–8.
  • 19
    Rogal SS, Poschman K, Belanger K, Howell HB, Smith MV, Medina J et al. Effects of posttraumatic stress disorder on pregnancy outcomes. J Affect Disord 2007;102:137–43.
  • 20
    Koopmans GT, Donker MC, Rutten FH. Length of hospital stay and health services use of medical inpatients with comorbid noncognitive mental disorders: a review of the literature. Gen Hosp Psychiatry 2005;27:44–56.
  • 21
    Chung EK, McCollum KF, Elo IT, Lee HJ, Culhane JF. Maternal depressive symptoms and infant health practices among low-income women. Pediatrics 2004;113:e523–9.
  • 22
    Mandl KD, Tronick EZ, Brennan TA, Alpert HR, Homer CJ. Infant health care use and maternal depression. Arch Pediatr Adolesc Med 1999;153:808–13.
  • 23
    Bartlett SJ, Krishnan JA, Riekert KA, Butz AM, Malveaux FJ, Rand CS. Maternal depressive symptoms and adherence to therapy in inner-city children with asthma. Pediatrics 2004;113:229–37.
  • 24
    Health NCfM. Guideline no. 45: Antenatal and Postnatal Mental Health. London: National Institue for Health and Clinical Excellence, 2007.
  • 25
    Hampton T. Antidepressants and pregnancy: weighing risks and benefits no easy task. JAMA 2006;295:1631–3.
  • 26
    Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368–75.
  • 27
    Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE 2008;3:e2782.
  • 28
    Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499–507.
  • 29
    Minkovitz CS, Strobino D, Scharfstein D, Hou W, Miller T, Mistry KB et al. Maternal depressive symptoms and children’s receipt of health care in the first 3 years of life. Pediatrics 2005;115:306–14.
  • 30
    Goodwin RD, Chuang S, Simuro N, Davies M, Pine DS. Association between lung function and mental health problems among adults in the United States: findings from the First National Health and Nutrition Examination Survey. Am J Epidemiol 2007;165:383–8.
  • 31
    Wyman PA, Moynihan J, Eberly S, Cox C, Cross W, Jin X et al. Association of family stress with natural killer cell activity and the frequency of illnesses in children. Arch Pediatr Adolesc Med 2007;161:228–34.
  • 32
    Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609–10.
  • 33
    Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898–906.
  • 34
    Gershon MD, Liu MT. Serotonin and neuroprotection in functional bowel disorders. Neurogastroenterol Motil 2007;19 Suppl. 2:19–24.
    Direct Link:
  • 35
    Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159: 1889–95.
  • 36
    Juttmann RE, Hess J, Looman CW, van der Maas PJ. Factors that determine the effectiveness of screening for congenital heart malformations at child health centres. Int J Epidemiol 2000;29:113–7.
  • 37
    Meyer-Wittkopf M, Simpson JM, Sharland GK. Incidence of congenital heart defects in fetuses of diabetic mothers: a retrospective study of 326 cases. Ultrasound Obstet Gynecol 1996;8:8–10.
    Direct Link:
  • 38
    Maher JE, Colvin EV, Samdarshi TE, Owen J, Hauth JC. Fetal echocardiography in gravidas with historic risk factors for congenital heart disease. Am J Perinatol 1994;11:334–6.
  • 39
    Stumpflen I, Stumpflen A, Wimmer M, Bernaschek G. Effect of detailed fetal echocardiography as part of routine prenatal ultrasonographic screening on detection of congenital heart disease. Lancet 1996;348:854–7.
View Full Article (HTML) Get PDF (222K)